Agios Pharmaceuticals AGIO Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's accrued expenses and other liabilities?
- Agios Pharmaceuticals (AGIO) reported accrued expenses and other liabilities of -$19.17M in Q1 2026.
- How has Agios Pharmaceuticals's accrued expenses and other liabilities changed year-over-year?
- Agios Pharmaceuticals's accrued expenses and other liabilities increased by 26.6% year-over-year, from -$26.1M to -$19.17M.
- What is the long-term trend for Agios Pharmaceuticals's accrued expenses and other liabilities?
- Over 2 years (2021 to 2024), Agios Pharmaceuticals's accrued expenses and other liabilities has grown at a 648.1% compound annual growth rate (CAGR), from $66K to $3.69M.